|1.||Bhatia, Vandanajay: 1 article (04/2012)|
|2.||Falzon, Miriam: 1 article (04/2012)|
|3.||Aronson, Judith F: 1 article (04/2012)|
|4.||Chao, Celia: 1 article (04/2012)|
|5.||Kim, Sung O K: 1 article (04/2012)|
|6.||Hellmich, Mark R: 1 article (04/2012)|
|7.||Takeuchi, Yasuhiro: 1 article (01/2011)|
|8.||Largo, R: 1 article (09/2001)|
|9.||Santos, S: 1 article (09/2001)|
|10.||Gazapo, R: 1 article (09/2001)|
01/01/2011 - "Thus, human PTHrP (1-36) is one of the promising drugs for treatment of osteoporosis."
08/01/1998 - "This uncoupling, if it were to continue over the longer term, would predict that PTHrP-(1-36) might be a potent anabolic therapeutic agent for osteoporosis."
10/01/1996 - "In this mini-review, the theoretical basis for the exploration and development of PTHrP(1-36) as a potential therapeutic agent for osteoporosis is considered."
03/01/1995 - "When tested in vitro, equivalent amounts of human PTHrp [1-36] did not produce significant bone resorption. "
01/01/2011 - "According to preclinical and some clinical data, daily subcutaneous injection of human PTHrP (1-36) could stimulate bone formation without a substantial increase in bone resorption or expected adverse events such as hypercalcemia. "
|3.||Osteosarcoma (Osteogenic Sarcoma)
|5.||Hypercalcemia (Milk Alkali Syndrome)
|1.||Parathyroid Hormone-Related Protein
|2.||Proliferating Cell Nuclear Antigen (PCNA)
|3.||Messenger RNA (mRNA)
|5.||Folic Acid (Vitamin M)